articleThe LancetJan 1, 2025Closed access

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

MKMasatoshi KudoZRZhenggang RenYGYabing GuoGHGuohong HanHLHailan Lin

Kindai University · Zhongshan Hospital · +35 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

230
total citations
FWCI
220.40
Percentile
100%
References
33
Citations per year

Authors

25

Topics & keywords

Topics
Keywords
  • Lenvatinib
  • Medicine
  • Pembrolizumab
  • Hepatocellular carcinoma
  • Placebo
  • Internal medicine
  • Oncology
  • Double blind
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.